Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.42 |
| ▸ | CHRNA2 | Q15822 | 6/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934205 | 0.94 | KCNH2 (0.42) | GRM5CHRNB2CHRNA2CHRNA4CHRNA3 | |
| SCHEMBL15544407 | 0.92 | KCNH2 (0.45) | GRM5CHRNB2CHRNA4MAPT | |
| SCHEMBL24642389 | 0.82 | CHRNB2 (0.47) | CHRNB2CHRNA2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL17050214 | 0.79 | GRM5 (0.48) | GRM5CHRNB2CHRNA4 | |
| SCHEMBL9741037 | 0.78 | CHRNB2 (0.46) | GRM5CHRNB2CHRNA2CHRNA4CHRNA3 | |
| SCHEMBL3673693 | 0.78 | CHRNB2 (0.69) | GRM5CHRNB2CHRNA4 | |
| SCHEMBL4913030 | 0.77 | CHRNB2 (0.38) | GRM5CHRNB2CHRNA2CHRNA4CHRNA3 | |
| SCHEMBL5886588 | 0.76 | FFAR1 (0.53) | — | |
| SCHEMBL9257177 | 0.75 | GRM5 (0.43) | GRM5CHRNB2CHRNA2CHRNA4CHRNA3 | |
| SCHEMBL8846653 | 0.74 | FFAR1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976351-B1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | MILTENYI BIOTEC GMBH (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-9803198-B2 | Lipohillic oligonucleotide analogs | MILTENYI BIOTEC, GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-2976351-A1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | Miltenyi Biotec GmbH (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-20160017325-A1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | MILTENYI BIOTEC GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2014147095-A1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | MILTENYI BIOTEC GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| EP-2781523-A1 | Lipophilic oligonucleotide analogs | Miltenyi Biotec GmbH (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-7485421-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST GMBH (DE) | 2009-02-03 | — | — | US | disclosed |
| US-6919441-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (US) | 2005-02-03 | — | — | US | disclosed |
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH | 2003-10-30 | — | — | US | disclosed |
| EP-0910634-A2 | ANTISENSE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEgF/VPF) EXPRESSION | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997039120-A2 | ANTISENSE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEFG/VPF) EXPRESSION | ARONEX PHARMACEUTICALS, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLR2H, POLN | GRM5 4102/4885CHRNB2 2016/4885CHRNA2 1883/4885 |
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLN, POLR2H | GRM5 4605/4885CHRNB2 2785/4885CHRNA2 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.